Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response

Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response

Patient-derived tissue culture models are valuable tools to investigate drug effects and targeted treatment approaches. Resected tumor slices cultured ex vivo have recently gained interest in precision medicine, since they reflect the complex microenvironment of cancer tissue. In this study, we exam...

Full description

Bibliographic Details
Main Authors:	Tímea Szekerczés, Arun Kumar Selvam, Carlos Fernández Moro, Soledad Pouso Elduayen, Joakim Dillner, Mikael Björnstedt, Mehran Ghaderi
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Antioxidants
Subjects:	patient-derived PDAC explants AHR pathway indole-3-pyruvic acid
Online Access:	https://www.mdpi.com/2076-3921/12/1/167

Similar Items

Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma
by: Carlos Fernández Moro, et al.
Published: (2022-08-01)

PKM2 is not required for pancreatic ductal adenocarcinoma
by: Alissandra L Hillis, et al.
Published: (2018-10-01)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
by: Allison N Lau, et al.
Published: (2020-07-01)

Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01)

Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)
by: Han Yin, et al.
Published: (2024-08-01)

Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreatic Ductal Adenocarcinoma
by: Daniela Carbone, et al.
Published: (2023-05-01)

Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression
by: Nayela N. Chowdhury, et al.
Published: (2024-01-01)

Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01)

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
by: Julie Dardare, et al.
Published: (2021-07-01)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
by: Tianjiao Li, et al.
Published: (2019-09-01)

Modulation of immunity by tryptophan microbial metabolites
by: Siying Li
Published: (2023-06-01)

Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma
by: Jennifer M. Cole, et al.
Published: (2019-09-01)

NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma
by: Tanya Schild, et al.
Published: (2021-06-01)

Analysis of single nuclear chromatin accessibility reveals unique myeloid populations in human pancreatic ductal adenocarcinoma
by: Hillary G. Pratt, et al.
Published: (2024-03-01)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
by: Jingchang Zhang, et al.
Published: (2022-07-01)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
by: Shantel Angstadt, et al.
Published: (2022-01-01)

Dietary L-Tryptophan Modulates the Structural and Functional Composition of the Intestinal Microbiome in Weaned Piglets
by: Haiwei Liang, et al.
Published: (2018-08-01)

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma
by: Julian Götze, et al.
Published: (2025-01-01)

Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma
by: I Gede Putu Supadmanaba, et al.
Published: (2022-04-01)

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma
by: Ke Cheng, et al.
Published: (2024-04-01)

The First Protocol for In Vitro Propagation of <i>Kalanchoe beharensis</i> Through Adventitious Shoots, a Preliminary Study
by: Ignacio Moreno-García, et al.
Published: (2024-12-01)

Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
by: Ningna Weng, et al.
Published: (2022-07-01)

Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
by: Irina Heid, et al.
Published: (2022-12-01)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
by: Yan Li, et al.
Published: (2022-01-01)

Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma
by: Cansu Tekin, et al.
Published: (2021-11-01)

[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
by: Felix N. Harder, et al.
Published: (2021-07-01)

Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma
by: Ann Mary Joseph, et al.
Published: (2024-02-01)

Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
by: Sophia Chikhladze, et al.
Published: (2019-11-01)

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01)

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
by: Na Sun, et al.
Published: (2021-12-01)

Design, Synthesis, and In Vitro Evaluation of Novel Indolyl DiHydropyrazole Derivatives as Potential Anticancer Agents
by: Katharigatta N. Venugopala, et al.
Published: (2021-08-01)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
by: Aimy Sebastian, et al.
Published: (2023-10-01)

CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma
by: Yi Cai, et al.
Published: (2018-01-01)

Brusatol increases chemotherapeutic drug efficacy in pancreatic ductal adenocarcinoma by suppressing Nrf2 signaling
by: Juan Zhang, et al.
Published: (2024-09-01)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
by: Chengkun Yang, et al.
Published: (2019-06-01)

Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling
by: Parthasarathy Seshacharyulu, et al.
Published: (2022-01-01)

The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma
by: Przemyslaw Grochowski, et al.
Published: (2024-06-01)

Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA
by: Martin Metzenmacher, et al.
Published: (2025-02-01)

Vitamin‐C‐dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest
by: Aiora Cenigaonandia‐Campillo, et al.
Published: (2024-09-01)

Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell models
by: Grazia Fenu, et al.
Published: (2024-10-01)